Optimized UV-Spectrophotometric Assay to Screen Bacterial Uricase Activity Using Whole Cell Suspension

Benoit Pugin¹, Serafina Plüss¹, Denisa Mujezinovic¹, Rikke C. Nielsen² and Christophe Lacroix*¹

¹Laboratory of Food Biotechnology, Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland, ²Beo Therapeutics AG, Zürich, Switzerland

Uricase catalyzes the conversion of uric acid into allantoin with concomitant reduction of molecular oxygen to hydrogen peroxide. In humans, uricase is not functional, thereby predisposing individuals to hyperuricemia, a metabolic disturbance associated with gout, chronic kidney disorders, and cardiovascular diseases. The efficacy of current therapies to treat hyperuricemia is limited, and novel approaches are therefore desired, for instance using uricase-expressing probiotic strains. Here, we evaluated UV-spectrophotometric and H₂O₂-based fluorescent assays to enable the rapid identification of uricase activity in a broad panel of lactobacilli, Bacillus, and Bifidobacterium species. We highlighted abiotic (medium composition and mode of sterilization) and biotic (H₂O₂-producing strains) factors impacting the measurements’ accuracy, and reported on the stepwise optimization of a simple, fast, and robust high-throughput UV-spectrophotometric method to screen uricase activity using whole bacterial suspension, thereby assessing both cell-associated and extracellular activity. The validity of the optimized assay, based on the monitoring of uric acid degradation at 300 nm, was confirmed via liquid chromatography. Finally, a panel of 319 Qualified Presumption of Safety (QPS) strains of lactobacilli (18 species covering nine genera), Bacillus (three species), and Bifidobacterium (four species) were screened for uricase activity using the optimized method. All 319 strains, but the positive control Bacillus sp. DSM 1306, were uricase-negative, indicating that this activity is rare among these genera, especially in isolates from food or feces. Altogether, the UV-spectrophotometric high-throughput assay based on whole bacterial suspension reported here can be used to rapidly screen large microbial collections, by simultaneously detecting cell-associated and extracellular uricase activity, thereby accelerating the identification of uricolytic strains with therapeutic potential to treat hyperuricemia.

Keywords: uricase, spectrophotometry, fluorescence, high-throughput screening, lactobacilli, Bacillus, Bifidobacterium
INTRODUCTION

Uricase (urate oxidase; EC 1.7.3.3) is an enzyme involved in purine metabolism, which catalyzes the conversion of uric acid (UA) into allantoin with concomitant reduction of molecular oxygen to hydrogen peroxide (Kahn and Tipton, 1998). It is expressed in a wide range of organisms, including bacteria, fungi, plants, and animals (Kahn and Tipton, 1998). In humans, uricase is not functional due to multiple evolutionary events, resulting in 3- to 10-fold higher serum UA levels compared to other mammals (Krätzer et al., 2014) and predisposing humans to hyperuricemia. Hyperuricemia is a metabolic disturbance affecting ~20% of the United States population (Zhu et al., 2011) and causes gout, chronic kidney disorders, and cardiovascular diseases (Wu et al., 1994; Culleton et al., 1999). Hyperuricemia is exacerbated by western diet (Siener and Hesse, 2003) or other diets rich in purines (Brulé et al., 1992), thus therapeutic strategies often include nutritional and lifestyle interventions though evidence for their efficacy is scarce (Moi et al., 2013). On the other hand, UA-lowering drugs (e.g., xanthine oxidase inhibitors such as allopurinol and febuxostat) are restricted to patients with severe or recurrent gout (Engel et al., 2017), as they exhibit potential adverse effects (Pacher et al., 2006) and limited long-term efficacy (Pérez-Ruíz et al., 2019). Therefore, novel approaches are desired.

The gastrointestinal tract plays an important role in UA metabolism and excretion (Méndez-Salazar and Martínez-Nava, 2021). In healthy people, UA is primarily cleared via the kidneys, though ~30% is excreted via the intestine (Sorensen and Levinson, 1975) where it can be further degraded by the gut microbiota (Chu et al., 2021). In line, recent studies have shown that the gut microbial community composition is significantly altered in rat models of hyperuricemia (Liu et al., 2020; Pan et al., 2020) or in patients with gout (Chu et al., 2021; Lin et al., 2021). The gastrointestinal tract may therefore constitute a promising therapeutic target for hyperuricemia, for instance using oral probiotic strains, a concept supported by recent in vivo studies with microbial uricase (Szczeruk et al., 2017) or uricolytic bacterial strains (García-Arroyo et al., 2018; Wu et al., 2021) that showed reduced serum UA levels in hyperuricemic rodent models.

To date, uricase activity was biochemically confirmed in various bacterial taxa, either extracellularly in Pseudomonas strains (Abdel-Fattah et al., 2005; Jagadeesan et al., 2019), or intracellularly in Arthrobacter (Suzuki et al., 2004), Microbacterium (Zhou et al., 2005; Kai et al., 2008), Streptomyces (Watanabe et al., 1969), Saccharopolyspora (Khuchareopenhia and Sinna, 2011), Micrococcus (Olivieri et al., 1983), Metabacillus (Zhang et al., 2010), and Bacillus (Mahler, 1970; Bongaerts and Vogels, 1976; Bongaerts et al., 1978; Huang and Wu, 2004; Lee et al., 2005; Lotfy, 2008) strains. In few lactobacilli strains, uricase activity was suggested to be present both intracellularly and extracellularly (Handayani et al., 2018), thus prompting further investigation of uricase in taxa associated with probiotic strains. The determination of bacterial uricase activity can be assessed either qualitatively, via the observation of UA consumption on UA-containing solid media (Shaaban et al., 2015; Pustake et al., 2019), or quantitatively, via the measurement of H2O2 formation using fluorescent dyes (Fraisse et al., 2002) or the determination of UA degradation using spectrophotometry (Koyama et al., 1996; Fraisse et al., 2002; Huang and Wu, 2004) or liquid chromatography (Safranow et al., 2000). Because of their simplicity and compatibility with microplate systems allowing parallel analysis of multiple samples, spectrophotometric and fluorescent techniques appear promising to develop a high-throughput screening assay for bacterial uricase activity. However, their non-specific nature may be source of analytical artefacts, especially in presence of bacterial cells or complex media such as those used for the growth of probiotic strains.

Here, we evaluated both spectrophotometric and fluorescent uricase activity assays and highlighted abiotic and biotic factors potentially impacting the measurements’ accuracy and bias. We reported on the stepwise optimization of a simple, fast, and robust high-throughput UV-spectrophotometric method to screen bacterial uricase activity using whole bacterial suspension, thereby assessing both cell-associated and extracellular uricase. Finally, a panel of 319 QPS (Qualified Presumption of Safety) strains of lactobacilli (nine genera), Bacillus, and Bifidobacterium, respectively representing 18, 3, and 4 species, were screened for uricase activity using the optimized UV-spectrophotometric method.

MATERIALS AND METHODS

Culture Media, Bacterial Strains, and Growth Conditions

The influence of eight different media on uricase activity measurement was evaluated, including: Lactobacillus Selection (LBS) and two different de Man, Rogosa, and Sharpe (MRS#1; NutriSelect™, Merck, Darmstadt, Germany. MRS#2; Biöfölt Italia Srl, Milan, Italy) media for lactobacilli; Luria–Bertani (LB; Sigma-Aldrich, St. Louis, United States) and Allantoin Mineral (AM) media for Bacillus species; and Bifidus Selective Medium (BSM; NutriSelect™, Merck), Reinforced Clostridial Medium (RCM), and Wilkins-Chalgren (WC; Oxoid™, Thermo Scientific, Waltham, United States) media for Bifidobacterium species. Additionally, 2-fold diluted (½) MRS#1, MRS#2 and WC were evaluated. The detailed composition of all media is presented in Supplementary File 1. Media were either autoclaved (~120°C, 20 min) or sterile filtered (~SF; Nalgene™ filter unit, 0.2 μm polyethersulfone membrane; Thermo Scientific). All media were freshly prepared the day before spectrophotometric and fluorescent measurements and stored at 4°C until analysis.

The 319 QPS strains used in this study (Supplementary Table S1) were obtained from our own collection, and consisted of 166 lactobacilli strains [18 species from nine genera; all formerly Lactobacillus (Zheng et al., 2020)], 110 Bacillus strains (three species), and 43 Bifidobacterium strains (four species) previously isolated from feces (human, mouse, and chicken) or fermented food products. Bacillus sp. DSM 1306 was acquired from the German Collection of Microorganisms and Cell Culture GmbH (DSMZ, Braunschweig, Germany). All strains were stored at ~80°C in 25% (v/v) glycerol stocks and routinely grown at 37°C in 96-deep-well plates (Nolato Treff AG, Degersheim, Switzerland).
Bacillus strains were grown aerobically in AM-Aut. Lactobacilli and Bifidobacterium strains were grown anaerobically using Oxoid™ AnaeroGen™ pouches (Thermo Scientific) in ½MRS#1-SF and ½WC-SF media, respectively. Prior to spectrophotometric and fluorescent analyses, the strains were reactivated in the corresponding media for 24h, and pre-cultures were then transferred (1%, v/v) in fresh media and grown for 24h before harvesting. When required, the medium was supplemented with 0.5mM (fully soluble) or 30mM (insoluble) uric acid.

UV-Spectrophotometric Determination of Uricase Activity

Absorbance spectra of the tested growth media, measured in absorbance units (AU), were determined between 250 and 350 nm in UV-transparent (acrylic; Corning Inc., New York, United States) or standard (polystyrene; SPL Life Sciences Co. Ltd., Gyeonggi-do, South Korea) 96-well plates by mixing 40μl medium with 160μl borate buffer (5 mM H₂BO₃, pH 8.5).

Spectrophotometric uricase activity was determined by monitoring the reduction of uric acid at 300 nm (AU₉₀₀), 37°C, aerobically, for 60 min in standard 96-well plate. The assay was initiated by mixing 40μl sample or uricase (70 mU/ml final concentration; product No. U0880, Sigma-Aldrich) with 160μl UA (0.5 mM final) in borate buffer. The samples tested included fresh medium, whole culture samples (cells and supernatant), supernatants (5,500 × g, 10 min, 4°C), or the cell pellet washed once and resuspended in PBS (pH 7.4). Uricase activity was calculated using the linear region of the spectrophotometric kinetic curve corresponding to the maximum reaction rate. Uric acid concentration was determined from absorbance readings using UA standard curves generated in the 0.1–0.5 mM range. One unit of uricase is defined as the amount of sample that consumes 1.0 μmol of UA per minute under the standard assay conditions.

All spectrophotometric analyses were performed with a preheated microplate spectrophotometer PowerWave™ XS (BioTek instruments, Winooski, United States).

Fluorescent Determination of Uricase Activity

Uricase activity was determined using the fluorescent Amplex™ Red Uric Acid/Uricase Assay Kit (Thermo Scientific) to quantify H₂O₂ production and was expressed as relative fluorescence units (RFU). Kinetics were performed at 37°C, aerobically, for 60 min in black 96-well plate with transparent bottom (polystyrene; Greiner Bio-One GmbH, Frickenhausen, Germany) in a preheated microplate fluorescent reader FL600 (BioTek instruments) with excitation and emission bandpass filters of 485/20 and 565/20 nm, respectively. All solutions were provided in the kit. Briefly, 20μl sample (medium or bacterial suspension) or uricase (5mU/ml final) was mixed with 69.3μl reaction buffer, 10μl UA (0.5 mM final), 0.2μl horseradish peroxidase (0.2 U/ml final), and 0.5μl Amplex Red (50μM final). Uricase activity was calculated using the linear region of the fluorescent kinetic curve corresponding to the maximum reaction rate. Hydrogen peroxide concentration was determined from fluorescent readings using H₂O₂ standard curves generated in the 0–0.01mM range. One unit of uricase is defined as the amount of sample that produces 1.0μmol of H₂O₂ per minute under the standard assay conditions.

Quantification of Uric Acid by Liquid Chromatography

Uric acid was quantified by Ultra High Performance Liquid Chromatography equipped with a Diode Array Detector (UHPLC-DAD), modified from Safranow et al. (2000). Uric acid 10 mM standard stock solution (analytical grade; Sigma-Aldrich) was prepared in 25 mM NaOH and was further diluted with MilliQ water to generate a standard curve. Bacterial suspensions were centrifuged (14,000 × g, 10 min, 4°C), and supernatants were filtered (0.45 μm nylon membrane filter) prior to UHPLC-DAD analysis. The separation was carried out with a Vanquish™ Flex UHPLC System (Thermo Scientific), coupled to an ACQUITY BEH C18 column (1.7 μm particle size, 2.1 × 100 mm; Waters Corp., Milford, United States). Samples (1 μl injection) were eluted at 24°C with a 0.2 ml/min flow rate under isocratic conditions using 50 mM phosphate buffer pH 5.5 / methanol (97/3, v/v) as mobile phase. UA was quantified using a Vanquish™ diode array detector at 300 nm. Data were processed using Chromeleon 7 software (Thermo Scientific).

RESULTS

Influence of Media Composition and Sterilization on Basal UV-Spectrophotometric Absorbance

We first evaluated whether the spectrophotometric quantification of UA could be impaired by major UV-absorbing compounds present in common growth media or generated during sterilization, i.e., autoclaved (Aut) vs. sterile filtered (SF). Absorbance spectra in a UV-transparent 96-well plate showed maximal absorbance of UA in the 280–300 nm range (>3.000 AU), while all media also displayed basal levels of absorbance, which decreased as wavelengths increased (Figure 1). In the maximal absorbance range of UA, the autoclaved medium MRS#2-Aut absorbed most, at level similar or higher than pure UA (≥3.000 AU), whereas ½WC, AM (Aut and SF) and sterile filtered ½MRS#1-SF absorbed least (<1.000 AU; Figure 1). The mode of sterilization had an important impact on the absorbance of most media, including RCM, BSM, LBS, MRS#1, ½MRS#1, MRS#2, and ½MRS#2, but not WC, ½WC, AM, and LB. Overall, autoclaved media displayed higher absorbance levels than sterile filtered media, which was particularly evident for LBS-Aut, MRS#1-Aut, and MRS#2-Aut with an AU increase of up to 1.51 (292–293 nm), 1.40 (290–296 nm), and 2.50 (296–297 nm) compared to their SF counterpart (Figure 1). Using a standard polypeptide 96-well plate, similar absorbance patterns were observed across the tested conditions, except for the strong plate absorbance measured at low wavelengths (>3.000 AU at ≤280 nm; Supplementary Figure S1) compared to UV-transparent 96-well plate. At 300nm, the polypeptide plate background absorbance was moderate (0.400AU), and this wavelength was thus selected for subsequent UV-spectrophotometric assessment.
of bacterial uricase activity with standard 96-well plate. It is worth noting that the UA precursor xanthine and the UA degradation product allantoin did not absorb at 300 nm (data not shown).

Influence of Media Composition and Sterilization on Fluorescent Measurements

We next evaluated whether growth media and their sterilization could also interfere with fluorescent assays based on the quantification of H$_2$O$_2$ as a marker byproduct of the uricase activity. All media displayed basal levels of fluorescence and surprisingly these intensities appeared to increase over time (Figure 2). The highest rates ($\Delta$RFU/$\Delta$time) were observed for MRS#2-Aut and RCM-SF, which would correspond to a uricase activity of 7.26 ± 0.18 and 7.41 ± 0.01 mU/ml, respectively (Supplementary Table S2). The mode of sterilization impacted the fluorescence.
measurements, with distinct intensities observed between Aut and SF conditions in RCM, BSM, LBS, MRS#1, MRS#1, MRS#1, ½MRS#1, MRS#2, ½MRS#2, and to a lesser extend in WC, ½WC, AM, and LB (Figure 2). However, autoclaved media did not always yield stronger fluorescence rates: LBS-Aut, MRS#1-Aut, ½MRS#1-Aut, MRS#2-Aut, and ½MRS#2-Aut showed higher fluorescence rates compared to their SF counterpart, whereas BSM-SF and RCM-SF showed higher fluorescence rates compared to their Aut counterpart (Figure 2).

Evaluation of Uricase Activity Using Whole Bacterial Suspension
To minimize the impact of the nutritional medium on UV-spectrophotometric and fluorescent analyses, ½MRS#1-SF, AM-Aut, and ½WC-SF were selected for the growth and screening of lactobacilli, Bacillus, and Bifidobacterium species, respectively. UV-spectrophotometric and fluorescent methods were then evaluated in presence of whole bacterial culture samples to measure simultaneously both extracellular and cell-associated uricase activity, and identify potential cofounding

FIGURE 2 | Fluorescence kinetics of uricase (5 mU/ml) compared to autoclaved (-Aut) or sterile filtered (-SF) complex media commonly used for the growth of lactobacilli, Bacillus, and Bifidobacterium species. RFU, relative fluorescence units. Data represent the mean and SD from two independent replicates.
Screening of Uricase Activity in Lactobacilli, *Bacillus*, and *Bifidobacterium* Species

Altogether, the UV-spectrophotometric assay emerged as the most simple, effective, and robust method for high-throughput screening of bacterial uricase activity, and was therefore used to screen a large panel of 319 QPS strains of lactobacilli \((n=166)\), *Bacillus* \((n=110)\), and *Bifidobacterium* \((n=43)\;\text{Supplementary Table S1}\.\) Beside the positive control *Bacillus* sp. DSM 1306, none of the strains from these genera showed reduction of absorbance at 300 nm over 60 min, indicating the absence of uricase activity under the tested conditions \((\text{Figure 4})\).

DISCUSSION

In this work, we evaluated two quantitative methods to develop a high-throughput screening approach of bacterial uricase activity in microtiter plates, with particular focus on conditions relevant to lactobacilli, *Bacillus*, and *Bifidobacterium* strains. Using a stepwise approach, we aimed at developing a sensitive, yet robust method using whole bacterial suspensions to enable the simultaneous detection of both extracellular and cell-associated uricase activities, thereby accelerating the screening of large microbial collections and the identification of uricolytic strains independently from the enzyme’s partition \((\text{Watanabe et al., 1969; Olivieri et al., 1983; Suzuki et al., 2004; Kai et al., 2008; Lotfy, 2008; Zhang et al., 2010; Khucharoenphaisan and Sinma, 2011; Handayan et al., 2018; Jagadeesan et al., 2019})\).

Our data revealed that the fluorescent assay, based on the quantification of \(\text{H}_2\text{O}_2\) released during UA degradation, was the least suitable method because of its susceptibility to biases derived from both abiotic and biotic factors. In absence of bacteria, many media exhibited strong background fluorescence intensities \((=\text{false positive})\), as exemplified by the fluorescence rates of MRS\#2-Aut and RCM-SF which corresponded to \(~20\%\) of the fluorescence rate of the uricase positive control *Bacillus* sp. DSM 1306 \((\text{Supplementary Table S2, Figure 3})\.\) This abiotically-generated fluorescence might have arisen from the spontaneous generation of \(\text{H}_2\text{O}_2\) as byproduct from the reactions between sugars, phosphate salts and proteinaceous components \((\text{e.g., tryptone, peptone, and yeast extract})\), especially during heat treatment \((\text{Finkelstein and Lankford, 1957; Carlsson et al., 1978; Nakashima et al., 2010})\.\)

More importantly, the fluorescent assay was prone to false positive signals in presence of bacterial cells \((\text{Figure 3})\.\) As previous studies showed that \(\text{H}_2\text{O}_2\) can be produced by various *Bifidobacterium* \((\text{Kawai et al., 2009})\) and lactobacilli \((\text{Pridmore et al., 2008; Martin and Suárez, 2010; Hertzberger et al., 2014})\) strains, the *H₂O₂*-based fluorescent assay appears unsuitable to screen uricase activity using whole bacterial suspensions.

In contrast, the UV-spectrophotometric method evaluated and optimized here can be used for the high-throughput screening of bacterial uricase activity. By monitoring UA degradation at 300 nm, we maximized the absorbance of UA and minimized the background absorbance of most tested complex media \((\text{Figure 1})\), while enabling the use of standard polystyrene 96-well plates \((\text{Supplementary Figure S1, Figure 4})\.\) To ensure the sensitivity of the spectrophotometric measurements, medium selection and preparation should be carefully considered though. Thermal sterilization by autoclaving consistently increased the background absorbance of most media \((\text{Figure 1})\), probably due to the reaction between reducing sugars \((\text{e.g., glucose})\) and proteinaceous components resulting in Maillard reaction products \((\text{Hemmler et al., 2017})\) that absorbed in the UV-Vis wavelengths range \((\text{Wang et al., 2016; Liu et al., 2018})\.\) The absence or low concentration of glucose in WC, \(\frac{1}{2}\text{WC}\), AM, and LB \((\text{Supplementary File 1})\) could explain the minor variations of absorbance observed between these media when autoclaved or filter sterilized \((\text{Figure 1})\.\) It is worth noting that autoclaved MRS, a media heavily used in laboratories to grow lactobacilli strains, were highly absorbing at UV wavelengths, thus hindering its compatibility with UV-spectrophotometric assays in general \((\text{Figure 1})\); nonetheless, those effects can be attenuated by using a diluted and sterile filtered version of this medium \((\text{Supplementary File 1})\.\)

The screening of 319 QPS strains of lactobacilli \((\text{nine genera})\), *Bacillus*, and *Bifidobacterium* using the optimized UV-spectrophotometric assay did not result in the identification of uricase positive strains, except for the positive control *Bacillus* sp. DSM 1306. Although we cannot fully discard the possibility of few false negative results from the high-throughput screening, previous reports on the regulation of bacterial uricase activity support the conditions tested here. Nitrogen- or carbon-limitation
was shown to stimulate uricase activity in resting cells of *Streptomyces* spp. (Watanabe et al., 1976), thereby validating the use of protein-depleted media to grow and assess bacterial uricase activity (i.e., $\frac{1}{2}$MRS#1-SF, AM-Aut, and $\frac{1}{2}$WC-SF; *Supplementary File 1*). In various *Bacillus* species, UA was shown to serve as a nitrogen source (Bongaerts and Vogels, 1976), and while no UA was

![UV-spectrophotometric kinetics](image1)

![Fluorescence kinetics](image2)

**FIGURE 3** | Evaluation of uricase activity using *Bacillus* (DSM 1306), lactobacilli (BT-4087 and BT-1025), and *Bifidobacterium* (BT-4055X and BT-4055Y) suspension (cells and supernatants) as determined by UV-spectrophotometric (absorbance at 300 nm) and fluorescence assays. Strains were grown in the corresponding medium for 24 h in presence or absence of 30 mM uric acid (UA). Data represent the mean and SD from two biological replicates.
supplemented in the culture media of the 319 tested strains, cells were grown in protein-depleted media, harvested in the stationary growth phase, and ultimately exposed to 0.5 mM UA for 60 min during uricase activity measurement (Figure 4). Besides, uricase activity was not promoted by the direct supplementation of UA in the growth media of four randomly tested strains, and the positive control Bacillus sp. DSM 1306 (Figure 3).

The data obtained from the 319 screened strains, representing a total of 11 genera and 25 species with several strains of the same species (Supplementary Table S1), strongly suggest that uricase activity is a rare feature in lactobacilli, Bacillus, and Bifidobacterium species, especially in strains isolated from fermented food products or from the gastrointestinal tract. Beside previous reports on uricase-positive Bacillus strains from soil samples (Mahler, 1970; Bongaerts and Vogels, 1976; Huang and Wu, 2004; Lotfy, 2008), no study have yet reported the presence of uricase in Bifidobacterium, and only two studies reported uricase activity in lactobacilli food isolates, i.e., Limosilactobacillus fermentum (Wu et al., 2021) and Lactiplantibacillus plantarum (Handayani et al., 2018). Considering that 40 L. fermentum and 29 L. plantarum strains (Supplementary Table S1) were tested uricase-negative in our screening, and that no uricase-encoding gene has yet been identified in lactobacilli genomes (in contrast to the uricase-encoding genes in Bacillus; Schultz et al., 2001), we question whether previous reports on lactobacilli uricase activity (Handayani et al., 2018; Wu et al., 2021) are the results of potential methodological biases as highlighted here for a broad panel of tested strains from 11 genera, or a less likely highly strain-specific feature.

Altogether, the whole bacterial suspension screening method developed here provides various advantages compared to the qualitative agar plate-based assay, as it is quantitative, specific, and scalable. Our approach can serve as a guide for the assessment of uricase activity in large and taxonomically diverse microbial collection, and therefore potentially supporting the identification of novel uricolytic strains with therapeutic potential for the treatment of hyperuricemia and associated comorbidities.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

BP, SP, DM, and CL designed the experiments. RN provided critical feedback on the study design. SP and DM performed the experiments. BP, SP, and DM performed data analysis. BP and CL wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by a grant from the Swiss Innovation Agency (40722.1 IP-LS), in collaboration with Beo Therapeutics AG. The research was conducted in the absence of any commercial relationships that could have influenced or biased the work presented here.

ACKNOWLEDGMENTS

We thank Alfonso Die (ETH Zürich) for his assistance with UHPLC-DAD analyses. We thank Stefanie Immler (Milian AG) for her outstanding support to obtain the material needed for this project.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.853735/full#supplementary-material
and evidence for a novel Regulon controlled by the PucR transcription activator. *J. Bacteriol.* 183, 3293–3302. doi: 10.1128/JB.183.11.3293-3302.2001

Shaaban, M. I., Abdelmegeed, E., and Ali, Y. M. (2015). Cloning, expression, and purification of recombinant Uricase enzyme from *Pseudomonas aeruginosa* Pvo3 using *Escherichia coli*. *J. Microbiol. Biotechnol.* 25, 887–892. doi: 10.4014/jmb.1410.10041

Siener, R., and Hesse, A. (2003). The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation. *Eur. J. Nutr.* 42, 332–337. doi: 10.1007/s00394-003-0428-0

Shaaban, M. I., Abdelmegeed, E., and Ali, Y. M. (2015). Cloning, expression, and purification of recombinant Uricase enzyme from *Pseudomonas aeruginosa* Pvo3 using *Escherichia coli*. *J. Microbiol. Biotechnol.* 25, 887–892. doi: 10.4014/jmb.1410.10041

Siener, R., and Hesse, A. (2003). The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation. *Eur. J. Nutr.* 42, 332–337. doi: 10.1007/s00394-003-0428-0

Suzuki, K., Sakasegawa, S.-I., Misaki, H., and Sugiyama, M. (2004). Molecular cloning and expression of uricase gene from *Arthrobacter globiformis* in *Escherichia coli* and characterization of the gene product. *J. Biosci. Bioeng.* 98, 153–158. doi: 10.1016/S1389-1723(04)00259-2

Szczeurek, P., Mosiuchuk, N., Woźniński, J., Yatsenko, T., Grujic, D., Lozinska, L., et al. (2017). Oral uricase eliminates blood uric acid in the hyperuricemic pig model. *PLoS One* 12:e0179195. doi: 10.1371/journal.pone.0179195

Wang, L., Jiang, Z., Tian, B., Bai, L., Shi, X., and Zhang, X. (2016). Effects of Galactose concentration on characteristics of angiotensin-I-converting enzyme inhibitory peptides derived from bovine casein in Maillard reaction. *Int. J. Food Prop.* 19, 2238–2250. doi: 10.1080/10942912.2015.1121397

Watanabe, Y., Ohe, T., and Morita, M. (1976). Control of the formation of Uricase in *Streptomyces* sp. By nitrogen and carbon sources. *Agric. Biol. Chem.* 40, 131–139. doi: 10.1080/00021369.1976.10862014

Watanabe, Y., Yano, M., and Fukumoto, J. (1969). Studies on the formation of Uricase by *Streptomyces*. *Agric. Biol. Chem.* 33, 1282–1290. doi: 10.1080/00021369.1969.10859469

Wu, X., Wakamiya, M., Vaishnav, S., Geske, R., Montgomery, C., Jones, P., et al. (1994). Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. *Proc. Natl. Acad. Sci. U. S. A.* 91, 742–746. doi: 10.1073/pnas.91.2.742

Wu, X., Ye, Z., Feng, P., Li, R., Chen, X., Tian, X., et al. (2021). Limosilactobacillus fermentum JL-3 isolated from “Jiangshui” ameliorates hyperuricemia by degrading uric acid. *Gut Microbes* 13, 1–18. doi: 10.1080/19490097.2021.1897211

Zhang, C., Yang, X., Feng, J., Yuan, Y., Li, X., Bu, Y., et al. (2010). Effects of modification of amino groups with poly(ethylene glycol) on a recombinant Uricase from *Bacillus fastidiosus*. *Biosci. Biotechnol. Biochem.* 74, 1298–1301. doi: 10.1271/bbb.100880

Zheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., et al. (2020). A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus *Beijerinck* 1901, and union of Lactobacillaceae and Leuconostocaceae. *Int. J. Syst. Evol. Microbiol.* 70, 2782–2858. doi: 10.1099/ijsem.0.004107

Zhou, X., Ma, X., Sun, G., Li, X., and Guo, K. (2005). Isolation of a thermostable uricase-producing bacterium and study on its enzyme production conditions. *Process Biochem.* 40, 3749–3753. doi: 10.1016/j.procbio.2005.05.002

Zhu, Y., Pandya, B. J., and Choi, H. K. (2011). Prevalence of gout and hyperuricemia in the US general population: the National Health and nutrition examination survey 2007–2008. *Arthritis Rheum.* 63, 3136–3141. doi: 10.1002/art.30520

**Conflict of Interest:** RN works for the company Beo Therapeutics AG.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pugin, Plüss, Majezinovic, Nielsen and Lacroix. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.